Shopsin B, Gershon S, Thompson H, Collins P
Arch Gen Psychiatry. 1975 Jan;32(1):34-42. doi: 10.1001/archpsyc.1975.01760190036004.
Lithium carbonate, haloperidol, and chlorpromazine hydrochloride were compared in a double-blind controlled study with severely ill hospitalized manics. Lithium carbonate and haloperidol produced a highly significant improvement of manic symptoms without sedation. Although producing considerable sedation, chlorpromazine did little to alter the underlying mania qualitatively. Qualitative differences between lithium carbonate and haloperidol indicate that, while haloperidol has a more dramatically rapid impact on behavior-motor activity, lithium carbonate acted more evenly on the entire manic picture, with total normalization realized during active treatment. The majority of lithium carbonate-treated patients met discharge criteria at study termination, but not the patients receiving either neuroleptic drug. The rating scales are not sensitive enough to monitor manic psychopathology; this accounts for the lack of statistically significant differences among drug groups at treatment termination, despite the widely disparate discharge rates.
在一项针对重症住院躁狂症患者的双盲对照研究中,对碳酸锂、氟哌啶醇和盐酸氯丙嗪进行了比较。碳酸锂和氟哌啶醇在不产生镇静作用的情况下,能使躁狂症状得到高度显著的改善。虽然氯丙嗪会产生相当程度的镇静作用,但在定性方面对潜在的躁狂症状几乎没有影响。碳酸锂和氟哌啶醇之间的定性差异表明,虽然氟哌啶醇对行为 - 运动活动的影响更为迅速显著,但碳酸锂对整个躁狂症状的作用更为均衡,在积极治疗期间实现了完全正常化。在研究结束时,大多数接受碳酸锂治疗的患者达到了出院标准,但接受任何一种抗精神病药物治疗的患者均未达到。评定量表对监测躁狂精神病理学不够敏感;这就解释了为何尽管出院率差异很大,但在治疗结束时各药物组之间缺乏统计学上的显著差异。